trending Market Intelligence /marketintelligence/en/news-insights/trending/frl4093EbmrhBoiCImYg_A2 content esgSubNav
In This List

Cosmo, RedHill Biopharma enter strategic collaboration for US rights to Aemcolo

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector

Blog

Insight Weekly: Energy reforms after midterms; Crisis ends 'age of gas'; bank deposits fall


Cosmo, RedHill Biopharma enter strategic collaboration for US rights to Aemcolo

Cosmo Pharmaceuticals NV and RedHill Biopharma Ltd. have entered into an exclusive license agreement for the U.S. rights to traveler's diarrhea drug Aemcolo.

As part of the deal, the Dublin-based pharmaceutical company will invest $36.3 million in RedHill at $7 per American depositary share, or ADS.

Tel-Aviv, Israel-based RedHill will have exclusive U.S. rights to commercialize Aemcolo, and Cosmo will be the exclusive supplier of the drug. The license agreement also provides for granting certain rights to RedHill for the potential development of additional uses for Aemcolo, as well as arrangements related to other potential products of Cosmo.

RedHill entered into the collaboration primarily to prepare for the launch of its oral capsule Talicia to treat H. pylori infection, the company said in an Oct. 18 press release.

In addition to the $36.3 million investment, RedHill will issue 1,714,286 ADSs valued at about $12 million to Cosmo as an up-front payment for the rights granted under the Aemcolo license. The Israeli pharmaceutical company will also pay Cosmo a royalty percentage on net sales of the drug in the U.S.

Under the license agreement, Cosmo is also eligible for potential regulatory and commercial milestone payments of up to $100 million and is entitled to nominate one member to RedHill's board.